Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692273 · ClinicalTrials.gov registry record · NA
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
A NA study of Burns and Hypertrophic Scar, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03692273: Completed NA study of Burns and Hypertrophic Scar, sponsored by Massachusetts General Hospital.
NCT03692273 is a NA study of Burns and Hypertrophic Scar that has completed, run by Massachusetts General Hospital. The registered enrollment target is 17 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03692273, a NA study of Burns and Hypertrophic Scar, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Laser treatment of hypertrophic burn scars has become increasingly popular for improving scarring in burn survivors. Despite its common use, there a gap in knowledge regrading randomized control trials that demonstrate whether the laser is beneficial. Such a trial is important because if it shows the laser does work, it would provide the evidence to make such treatments more accessible to all patients. Furthermore, there is no knowledge whether the burn injury used to remove tissue is beneficial or not. This study aims to evaluate the laser treatment, removal of similar tissue amounts with 0.5mm punch biopsies, to controls to fill this knowledge gap. The hypothesis is the laser is beneficial at improving patient's burn scars. Also the punch biopsies work better at improving scars by removing tissue without burning and injuring the surrounding tissue as the laser does. To evaluate these treatments (laser, punch biopsies, and no treatment), 3 small areas will be chosen in a study scar area that meets specific criteria to receive . Patients will still be able to receive laser and burn reconstruction procedures in all other areas not involving the study scar area that are clinically indicated. In the study, the scar will be evaluated with photographs, surveys, and tissue samples taken either while under anesthesia except for one set taken with numbing medicine. The tissue samples will be looked at under a microscope to see how the treatments change the scar tissue. The tissue will also have tests done to evaluate how the laser impacts genes from cells in the scar tissue. Lastly, to understand how reconstructive procedures (laser and surgical treatments) change a patient's quality of life, patients will be asked a limited set of questions to learn more how these procedures improve their lives.
Primary Outcome
scar scale to evaluate severity of hypertrophic burn scars This is a 3 question scale, the first question graded from 0-3, the second and third questions graded from 0-5. The final score is the sum of the scores of the three questions, giving a possible total score range of 0-13. The higher the score, the worse the outcome.
Conditions Studied
Interventions
- PROCEDURE Luminis ultrapulse fractional ablative carbon dioxide laser
- PROCEDURE 0.5mm punch biopsy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2025-10-06 |
| Phase | NA |
What the finished NCT03692273 record still lists
NCT03692273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Luminis ultrapulse fractional ablative carbon dioxide laser is the first listed.
NCT03692273 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03692273 about?
NCT03692273 is a clinical study titled "Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar". Laser treatment of hypertrophic burn scars has become increasingly popular for improving scarring in burn survivors. Despite its common use, there a gap in knowledge regrading randomized control trials that demonstrate whether the laser is beneficial. Such a trial is important because if it shows th...
What is the current status of trial NCT03692273?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-03-20. Estimated completion is 2025-10-06.
What conditions does trial NCT03692273 study?
This clinical trial studies the following conditions: Burns, Hypertrophic Scar.
What interventions are being tested in trial NCT03692273?
The interventions under investigation include: Luminis ultrapulse fractional ablative carbon dioxide laser (PROCEDURE), 0.5mm punch biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03692273?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03692273 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03692273's enrollment target sits among peer trials
17 28th of 36 higher than 9 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery
RECRUITING · NA
-
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
ACTIVE NOT RECRUITING · NA
-
Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation
ACTIVE NOT RECRUITING · NA
-
Virtual Reality in Burn Pain Management
COMPLETED · NA
-
VR for Pain Management During Adult Burn Dressing Change
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI